SG11201811595SA - Liponucleotide-based therapy for ards - Google Patents
Liponucleotide-based therapy for ardsInfo
- Publication number
- SG11201811595SA SG11201811595SA SG11201811595SA SG11201811595SA SG11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA SG 11201811595S A SG11201811595S A SG 11201811595SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cdp
- rule
- ards
- pct
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 abstract 2
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355096P | 2016-06-27 | 2016-06-27 | |
| PCT/US2017/039545 WO2018005527A1 (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811595SA true SG11201811595SA (en) | 2019-01-30 |
Family
ID=60786443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811595SA SG11201811595SA (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10874684B2 (de) |
| EP (2) | EP4292651A3 (de) |
| JP (1) | JP2019518798A (de) |
| KR (1) | KR20190022682A (de) |
| CN (1) | CN109475554A (de) |
| AU (1) | AU2017289278A1 (de) |
| CA (1) | CA3029005A1 (de) |
| SG (1) | SG11201811595SA (de) |
| WO (1) | WO2018005527A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3029005A1 (en) * | 2016-06-27 | 2018-01-04 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| US11154621B2 (en) | 2017-06-27 | 2021-10-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for COPD |
| WO2021202735A1 (en) * | 2020-03-31 | 2021-10-07 | Diffusion Pharmaceuticals Llc | The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease |
| US20230218556A1 (en) * | 2020-05-01 | 2023-07-13 | Irazu Bio | Method for treating respiratory viral infections comprising administration of fatty acid compositions |
| WO2023173043A1 (en) * | 2022-03-11 | 2023-09-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection |
| WO2023177995A2 (en) * | 2022-03-18 | 2023-09-21 | Ohio State Innovation Foundation | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| AU2789989A (en) * | 1987-10-28 | 1989-05-23 | Pro-Neuron, Inc. | Acylated uridine and cytidine and uses thereof |
| JP4408450B2 (ja) * | 1994-07-01 | 2010-02-03 | ウェルスタット セラピューティクス コーポレイション | 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体 |
| US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| US20030181353A1 (en) * | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| US20040049022A1 (en) * | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
| EP1408987B1 (de) * | 2001-07-13 | 2013-04-10 | Paratek Pharmaceuticals, Inc. | Tetracyclin-verbindungen mit therapeutischen zielaktivitäten |
| JP4716655B2 (ja) * | 2001-11-21 | 2011-07-06 | ユニバーシティ・オブ・オーフース | 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 |
| AU2006251562B2 (en) * | 2005-05-23 | 2012-03-22 | Massachusetts Institute Of Technology | Compositions containing PUFA and methods of use thereof |
| CN101506218A (zh) * | 2005-05-23 | 2009-08-12 | 麻省理工学院 | 含有多不饱和脂肪酸的组合物及其使用方法 |
| CA3029005A1 (en) * | 2016-06-27 | 2018-01-04 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| US11154621B2 (en) * | 2017-06-27 | 2021-10-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for COPD |
| US11850283B2 (en) * | 2017-06-27 | 2023-12-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for asthma |
-
2017
- 2017-06-27 CA CA3029005A patent/CA3029005A1/en active Pending
- 2017-06-27 CN CN201780039385.4A patent/CN109475554A/zh active Pending
- 2017-06-27 KR KR1020197002042A patent/KR20190022682A/ko not_active Application Discontinuation
- 2017-06-27 EP EP23207788.3A patent/EP4292651A3/de active Pending
- 2017-06-27 EP EP17821089.4A patent/EP3474853A4/de not_active Withdrawn
- 2017-06-27 JP JP2019519626A patent/JP2019518798A/ja active Pending
- 2017-06-27 AU AU2017289278A patent/AU2017289278A1/en not_active Abandoned
- 2017-06-27 WO PCT/US2017/039545 patent/WO2018005527A1/en unknown
- 2017-06-27 SG SG11201811595SA patent/SG11201811595SA/en unknown
-
2018
- 2018-12-21 US US16/230,225 patent/US10874684B2/en active Active
-
2020
- 2020-11-19 US US16/952,557 patent/US20210069225A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475554A (zh) | 2019-03-15 |
| AU2017289278A1 (en) | 2019-01-17 |
| EP4292651A2 (de) | 2023-12-20 |
| EP3474853A1 (de) | 2019-05-01 |
| EP4292651A3 (de) | 2024-03-13 |
| WO2018005527A1 (en) | 2018-01-04 |
| CA3029005A1 (en) | 2018-01-04 |
| EP3474853A4 (de) | 2020-02-19 |
| JP2019518798A (ja) | 2019-07-04 |
| US20190134074A1 (en) | 2019-05-09 |
| US20210069225A1 (en) | 2021-03-11 |
| US10874684B2 (en) | 2020-12-29 |
| KR20190022682A (ko) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811595SA (en) | Liponucleotide-based therapy for ards | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201408810TA (en) | Methods of treating arthritis | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201806419RA (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
| SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201805001UA (en) | Method of treating influenza a |